LCZ696, also known as sacubitril/valsartan, is a fixed-dose combination medication used primarily in the management of heart failure. It combines two active components: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB). This medication is specifically indicated for the treatment of heart failure with reduced ejection fraction (HFrEF).
Mechanism of Action
LCZ696 works through complementary mechanisms provided by its two components:
Sacubitril: Inhibits neprilysin, an enzyme that breaks down natriuretic peptides, bradykinin, and other vasoactive peptides. By inhibiting neprilysin, sacubitril increases the levels of these peptides, which leads to diuresis (increased urine production), vasodilation (widening of blood vessels), and reduced neurohormonal activation, all of which contribute to decreased heart failure symptoms and improved cardiac function.
Valsartan: Blocks the angiotensin II type 1 receptor, which prevents the action of angiotensin II, a hormone that promotes vasoconstriction (narrowing of blood vessels), sodium retention, and increased blood pressure. By blocking this pathway, valsartan helps to lower blood pressure and reduce the workload on the heart.
Indications
LCZ696 is indicated for:
Heart Failure with Reduced Ejection Fraction (HFrEF) : It is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients.
Dosage and Administration
LCZ696 is administered orally, typically as a tablet taken twice daily. The initial dosage is usually based on the patient's prior treatment with other medications, such as angiotensin-converting enzyme (ACE) inhibitors or ARBs. Dosage adjustments may be made based on tolerability and the patient’s clinical response.
Side Effects
Common side effects associated with LCZ696 may include:
Hypotension (low blood pressure)
Hyperkalemia (increased potassium levels in the blood)
Renal impairment (kidney function issues)
Cough
Dizziness or lightheadedness
Serious side effects can include angioedema (swelling beneath the skin), particularly in patients with a history of angioedema related to ACE inhibitors.
Drug Interactions
LCZ696 may interact with other medications, particularly those affecting blood pressure or renal function. It is important for healthcare providers to evaluate a patient's complete medication regimen to manage potential interactions effectively. Special consideration should be given to diuretics, other antihypertensive agents, and potassium-sparing diuretics.
Safety and Precautions
Several considerations should be taken into account when using LCZ696:
Monitoring: Regular monitoring of blood pressure, renal function, and potassium levels is recommended, especially after initiation or dose adjustment.
Pregnancy: LCZ696 is contraindicated in pregnancy due to potential harm to fetal development. Women of childbearing potential should use effective contraception while on this medication.
Contraindications: LCZ696 is contraindicated in patients with a history of angioedema related to ACE inhibitor or ARB therapy, in those with severe renal impairment, and in patients with a hypersensitivity to any component of the medication.
Regulatory Status
LCZ696 has been approved for use in numerous countries for the management of heart failure. Regulatory health authorities provide guidelines for its use, aiming to optimize patient outcomes while minimizing risks.
Conclusion
LCZ696 (sacubitril/valsartan) represents a significant advancement in the treatment of heart failure with reduced ejection fraction. Its dual mechanism of action effectively addresses multiple pathways involved in heart failure pathology. Careful monitoring and management of side effects are essential for optimizing treatment outcomes in patients using this medication.
LCZ696, also known as sacubitril/valsartan, is a fixed-dose combination medication used primarily in the management of heart failure. It combines two active components: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB). This medication is specifically indicated for the treatment of heart failure with reduced ejection fraction (HFrEF).
Mechanism of Action
LCZ696 works through complementary mechanisms provided by its two components:
Sacubitril: Inhibits neprilysin, an enzyme that breaks down natriuretic peptides, bradykinin, and other vasoactive peptides. By inhibiting neprilysin, sacubitril increases the levels of these peptides, which leads to diuresis (increased urine production), vasodilation (widening of blood vessels), and reduced neurohormonal activation, all of which contribute to decreased heart failure symptoms and improved cardiac function.
Valsartan: Blocks the angiotensin II type 1 receptor, which prevents the action of angiotensin II, a hormone that promotes vasoconstriction (narrowing of blood vessels), sodium retention, and increased blood pressure. By blocking this pathway, valsartan helps to lower blood pressure and reduce the workload on the heart.
Indications
LCZ696 is indicated for:
Heart Failure with Reduced Ejection Fraction (HFrEF) : It is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients.
Dosage and Administration
LCZ696 is administered orally, typically as a tablet taken twice daily. The initial dosage is usually based on the patient's prior treatment with other medications, such as angiotensin-converting enzyme (ACE) inhibitors or ARBs. Dosage adjustments may be made based on tolerability and the patient’s clinical response.
Side Effects
Common side effects associated with LCZ696 may include:
Hypotension (low blood pressure)
Hyperkalemia (increased potassium levels in the blood)
Renal impairment (kidney function issues)
Cough
Dizziness or lightheadedness
Serious side effects can include angioedema (swelling beneath the skin), particularly in patients with a history of angioedema related to ACE inhibitors.
Drug Interactions
LCZ696 may interact with other medications, particularly those affecting blood pressure or renal function. It is important for healthcare providers to evaluate a patient's complete medication regimen to manage potential interactions effectively. Special consideration should be given to diuretics, other antihypertensive agents, and potassium-sparing diuretics.
Safety and Precautions
Several considerations should be taken into account when using LCZ696:
Monitoring: Regular monitoring of blood pressure, renal function, and potassium levels is recommended, especially after initiation or dose adjustment.
Pregnancy: LCZ696 is contraindicated in pregnancy due to potential harm to fetal development. Women of childbearing potential should use effective contraception while on this medication.
Contraindications: LCZ696 is contraindicated in patients with a history of angioedema related to ACE inhibitor or ARB therapy, in those with severe renal impairment, and in patients with a hypersensitivity to any component of the medication.
Regulatory Status
LCZ696 has been approved for use in numerous countries for the management of heart failure. Regulatory health authorities provide guidelines for its use, aiming to optimize patient outcomes while minimizing risks.
Conclusion
LCZ696 (sacubitril/valsartan) represents a significant advancement in the treatment of heart failure with reduced ejection fraction. Its dual mechanism of action effectively addresses multiple pathways involved in heart failure pathology. Careful monitoring and management of side effects are essential for optimizing treatment outcomes in patients using this medication.
FAQ
Q1. Can I get a free sample?
We can send you a samll free sample, and you only need to pay for the shipping cost.
Q2. What is the HyperChem payment term?
T/T in advance
LC at sight
DP at sight
Bank transfer
PayPal
Bitcoin...
Q3. What is HyperChem shipment policy?
Our policy is to strive for the quickest shipment time possible.
For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.
Q4. What is HyperChem shipment term?
By Express
FedEx UPS DHL EMS
Fast: 3-7 days around, high cost, door to door service
By Air
Suitable for more than 50kg
Fast: 3-7 days, hight cost, port to port, professional broker needed
By Sea
Suitable for more than 500kg
Fast: 7-45 days, low cost, port to port, professional broker needed
We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.
Q5. What HyperChem will provide after shipment?
For sample orders:
After shipment is done, an timely email including:
1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice
For commercial orders:
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.
United Kingdom
